MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.480
+0.010
+0.29%
After Hours: 3.490 +0.01 +0.29% 19:08 11/25 EST
OPEN
3.420
PREV CLOSE
3.470
HIGH
3.510
LOW
3.420
VOLUME
92.90K
TURNOVER
--
52 WEEK HIGH
8.65
52 WEEK LOW
2.920
MARKET CAP
15.81M
P/E (TTM)
-1.1600
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dosing underway in Bio-Path's early-stage BP1002 study
Bio-Path Holdings (BPTH) enrolls the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia ((CLL)) patients. A total of
Seekingalpha · 11/19 13:09
Bio-Path Holdings Late Thursday Reported Q3 EPS $(0.80) Beats $(0.87) Estimate
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.87) by 8.05 percent. This is a 2.56 percent decrease over losses of $(0.78) per share from
Benzinga · 11/13 12:04
Intel, Limelight Networks among major Technology premarket losers' pack
KBS Fashion Group (KBSF) -20%.Puhui Wealth Investment Management (PHCF) -19%.Milestone Pharmaceuticals (MIST) -19% after pricing $45M equity offering.Limelight Networks (LLNW) -18% downgraded at Craig-Hallum after profit miss, margin weakness.Neovasc (NVCN) -15%.Sigma Labs (SGLB) -14% after Q3
Seekingalpha · 10/23 12:24
Mid-Afternoon Market Update: Dow Jumps 200 Points; Align Technology Shares Climb After Q3 Results
Toward the end of trading Thursday, the Dow traded up 0.71% to 28,411.36 while the NASDAQ rose 0.29% to 11,518.30. The S&P also rose, gaining 0.61% to 3,456.52.
Benzinga · 10/22 18:35
Mid-Day Market Update: Crude Oil Rises 2%; InVivo Therapeutics Shares Plummet
Midway through trading Thursday, the Dow traded up 0.04% to 28222.99 while the NASDAQ fell 0.22% to 11,459.67. The S&P also rose, gaining 0.01% to 3,436.
Benzinga · 10/22 16:49
ALGN, AHT, NVIV and TMBR among midday movers
Gainers: Ever-Glory International (EVK) +300%.Sequential Brands (SQBG) +106%.TuanChe (TC) +58%.Hexindai (HX) +34%.Align Technology (ALGN) +33%.KBS Fashion (KBSF) +27%.Ashford Hospitality Trust (AHT) +24%.Bio-Path (BPTH) +21%.First Internet Bancorp (INBK) +20%.LMP Automotive (LMPX) +18%.Losers: InVivo Therapeutics  (NVIV) -45%.Insignia
Seekingalpha · 10/22 16:38
Align Technology, Bio-Path Holdings leads healthcare gainers; InVivo Therapeutics, Teligent among major losers
Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Aptinyx (APTX) -21%, Iterum Therapeutics (ITRM) -20%, Timber Pharmaceuticals (TMBR) -18%.
Seekingalpha · 10/22 15:04
ALGN, SDC among premarket gainers
Ever-Glory International (EVK) +115%.Align Technology (ALGN +27% on Q3 results.Bio-Path Holdings (BPTH) +24%. onHelix Energy Solutions Group (HLX +16% on Q3 results.OptiNose (OPTN +14% on preliminary Q3 results.KBS Fashion Group (KBSF) +14%.Marathon Patent Group (MARA) +12%.SmileDirectClub
Seekingalpha · 10/22 12:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPTH. Analyze the recent business situations of Bio-Path Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPTH stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 728.75K
% Owned: 16.05%
Shares Outstanding: 4.54M
TypeInstitutionsShares
Increased
6
34.82K
New
5
-50.26K
Decreased
2
10.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Martina Molsbergen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.